Swiss biotech Santhera is on the brink of its first regulatory approval for Duchenne muscular dystrophy treatment vamorolone, after getting a positive opinion on the drug
Swiss biotech Santhera has found a North American partner for its Duchenne muscular dystrophy (DMD) therapy vamorolone, ahead of an FDA decision on the drug due by 26th Oc
AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceut